MX2012005155A - Compuestos de quinazolina. - Google Patents

Compuestos de quinazolina.

Info

Publication number
MX2012005155A
MX2012005155A MX2012005155A MX2012005155A MX2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A
Authority
MX
Mexico
Prior art keywords
quinazoline compounds
compounds
quinazoline
formula
disclosed
Prior art date
Application number
MX2012005155A
Other languages
English (en)
Inventor
Joanne Philp
Lara S Kallander
Brian Griffin Lawhorn
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2012005155A publication Critical patent/MX2012005155A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos que tienen la fórmula (ver formula). en donde R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente, y métodos para hacer y utilizar los mismos.
MX2012005155A 2009-11-03 2010-11-01 Compuestos de quinazolina. MX2012005155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (1)

Publication Number Publication Date
MX2012005155A true MX2012005155A (es) 2012-08-31

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005155A MX2012005155A (es) 2009-11-03 2010-11-01 Compuestos de quinazolina.

Country Status (13)

Country Link
US (1) US8859571B2 (es)
EP (1) EP2501233B1 (es)
JP (1) JP5836963B2 (es)
KR (1) KR101736521B1 (es)
CN (1) CN102711474B (es)
AU (1) AU2010315361B2 (es)
BR (1) BR112012010524A2 (es)
CA (1) CA2779989A1 (es)
EA (1) EA021439B1 (es)
ES (1) ES2523465T3 (es)
IL (1) IL219504A (es)
MX (1) MX2012005155A (es)
WO (1) WO2011056740A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603883B2 (ja) * 2009-02-17 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−Ｒａｆキナーゼを阻害するためのピリミドピリミジン誘導体
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法
CN105916506B (zh) * 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
KR102291455B1 (ko) 2013-12-26 2021-08-23 엑손모빌 리서치 앤드 엔지니어링 컴퍼니 Zsm-48 결정의 합성
JP2020536855A (ja) * 2017-09-26 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
KR20250005041A (ko) 2021-09-23 2025-01-09 에라스카, 아이엔씨. Egfr 억제제 다형체 형태

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
NZ567851A (en) * 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases

Also Published As

Publication number Publication date
JP5836963B2 (ja) 2015-12-24
EP2501233A1 (en) 2012-09-26
US20120220588A1 (en) 2012-08-30
EA021439B1 (ru) 2015-06-30
WO2011056740A1 (en) 2011-05-12
AU2010315361A1 (en) 2012-05-24
KR20120112441A (ko) 2012-10-11
KR101736521B1 (ko) 2017-05-16
CN102711474B (zh) 2014-09-10
BR112012010524A2 (pt) 2017-12-12
JP2013510155A (ja) 2013-03-21
ES2523465T3 (es) 2014-11-26
IL219504A0 (en) 2012-06-28
US8859571B2 (en) 2014-10-14
EP2501233A4 (en) 2013-06-19
EA201290243A1 (ru) 2012-12-28
IL219504A (en) 2016-09-29
EP2501233B1 (en) 2014-09-24
CN102711474A (zh) 2012-10-03
CA2779989A1 (en) 2011-05-12
AU2010315361B2 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
MX2012008141A (es) Compuestos y metodos.
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
PH12014500434A1 (en) New dihydroquinoline-2-one derivatives
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MY165238A (en) Substituted pyrrolidine-2-carboxamides
IN2015DN00960A (es)
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
PH12014500814A1 (en) New aryl-quinoline derivatives
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
MX2012005155A (es) Compuestos de quinazolina.
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.
PH12015500399A1 (en) Azaindolines
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.
IN2013MN01107A (es)
UA87793C2 (ru) 3-амино-1,1,1-трифторопропан-2-сульфонат натрия
UA36194U (en) Use of quercetin as hepatoprotector

Legal Events

Date Code Title Description
FG Grant or registration